HCV Associated Nephropathy

We analyzed the clinicopathological features and therapy in 19 patients with kidney disease accompanied by hepatitis C viral infection, including 12 patients with mesangial proliferative glomerulonephritis (including eight with IgA nephropathy), six with membranoproliferative glomerulonephritis (MPGN), and one with membranous nephropathy. Persistent hematuria and/or proteinuria (10 patients) was the most common finding, followed by nephrotic syndrome (8 patients). Cryoglobulinemia was detected in six of 19 patients examined (four of six patients with MPGN), Analysis of hepatitis C virus (HCV)-RNA genotype in 13 patients revealed that nine of them had type II genotype. All four patients with MPGN, who had serum positive for HCV-RNA, had type II genotype. Five patients were treated with interferon-alpha (IFN-alpha) without a demonstrable effect on renal impairment, whereas five of 11 patients treated with steroids showed improvement of the renal impairment. During the course of steroid therapy, the serum titer of HCV-RNA decreased in 5 of 7 patients. These observations suggest that HCV infection may be associated with several forms of glomerulonephritis. Type II HCV-RNA may have a strong association with MPGN in Japan. Steroid therapy is not contraindicated in patients with HCV-associated nephropathy if they are resistant to IFN-alpha treatment.

INTERNAL MEDICINE 1996 JUL;35(7):529-533 Authors: KOMATSUDA A, IMAI H, WAKUI H, HAMAI K, OHTANI H, KODAMA T, OYAMA Y, MIURA AB, NAKAMOTO Y

Advertisement
Hepatitis C Primer Home

What is Hepatitis How is Hepatitis Transmitted

Long-term Prognosis

Complications of HCV Liver Biopsy Treatment Info (Interferon, Herbal, etc) Lab Tests (PCR, Genotype,etc.) Nutrition & Alternative Info

Patient Information (Support Groups, Doctor Listing, etc) Related Webpages Transplant Info Site Search HCV Webrings Guestbook FAQ & Disclaimers

Key Findings About HCV Genotype 3
Learn about the clinical data which suggests that interferon-free regimens containing Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's NS5A inhibitor daclatasvir have advantages over currently available regimens for HCV genotype-3 infections.

Diet Supplement Tied to Hepatitis
Did you know that close to 100 people have unintentionally suffered from hepatitis because they took a popular weight loss product?

New Hepatitis C Study Cures 90% of Patients
Learn more about the combination of two anti-viral drugs (daclatasvir and asunaprevir) developed by Bristol-Myers Squibb Co that has been highly effective and well tolerated among study participants.

More Hep C articles ...